New Ideas.
Better Results.

Blue Matter is a consulting firm serving the life sciences industry. We strive to bring a new approach to consulting with original ideas that deliver a meaningful impact.

Contact Us

Our Purpose

We are proud to be part of an industry that is pushing the boundaries of science and technology to improve people’s lives. Our role is to help our clients identify unique insights, generate new ideas and drive meaningful results to get the most out of their products, portfolios and teams.

We began our careers in established consulting firms where we developed valuable experience and industry knowledge. During this time, we came to see that rigid processes often interfered with original thinking and led to bloated deliverables packed with mediocre answers.

A group of us like-minded, passionate consultants believed there was a better approach and founded Blue Matter to provide a platform to foster innovation and creativity in consulting.

Our Difference

Industry and scientific knowledge, analysis and insights. Left brain thinking. This is the foundation of our discipline. Creativity and imagination. Constantly challenging conventional thinking and seeking fresh ideas. Right brain thinking. We’re passionate about this; it’s the reason our clients come back.

The key to winning is effective differentiation. And effective differentiation comes from originality–thinking that is grounded in reason and infused with imagination.

"The terrific work you did resulted in a substantial change to our commercial strategy."

- Chairman of the Board, Small Biotech

"Thank you very much for the great work and partnership. You are one of the rare breed of consultants whom I trust. You will always be on my speed dial if we need help with anything."

- Chief Commercial Officer, Small Biotech

"I appreciate all of the great work you have done for our team this past year and look forward to continued partnership in the New Year."

- Chief Commercial Officer, Mid-sized Diagnostic Company

"Your preparation and support has been instrumental in achieving our desired outcome."

- Franchise Commercial Lead, Global Biotech

"Thank you all so much for the extremely successful project...I couldn't be happier with the way that it went."

- Sr. Product Manager, Diagnostic Company

"This project was excellent, from the content development to facilitation. Many, many thanks for the great work!"

- Director of Marketing, Diagnostic Company

"The process was great, I loved that I didn't have to manage you that much. Everything was highly organized and done on time. Quality and originality of thinking was also good."

- Global Commercial Lead, Large Biotech

"Great project. I was learning as we went along; good expertise — brought in examples from other projects."

- Global Commercial Lead, Large Biotech

Our Clients

Our clients include: top global bio-pharmaceutical companies with large, diverse product portfolios to small emerging players with one asset in development, leading diagnostic companies, and investment houses. We work with CEOs, Chief Commercial Officers, Franchise Heads, Product Directors, Functional Area Leaders. 90%+ of our business is from repeat, satisfied customers.

Our Services

Shape Innovative Products

Drive Successful Launches

Build Great Portfolios and Companies

Want to Join Our Team?

Blue Matter offers enriching project experiences with a diverse range of strategic, client-facing projects in the exciting and innovative life sciences industry.

Join Our Team

Insights

New Article: Here's a look at the complex array of stakeholders #biopharma companies must engage with in today's… https://t.co/rmBrBC2HhS

When & how will #GeneTherapy finally realize its commercial potential? See what our panel of experts had to say at… https://t.co/rxHetGnsGq

The Complex Oncology Audience

Part Three in a Six-Part Series on Oncology Product Commercialization In Part One of this series, we outlined five commercial challenges in oncology that biopharma decision-makers must face.  Part Two dealt with the first of those challenges, the “constant state of launch” that now exists in oncology.  In this installment, we introduce the complex array … Read More

The Disruptive Potential of Gene Therapy: When will it fully realize its commercial potential?

Gene therapy has made significant advances over the past few years.  However, those therapeutic advances have not been accompanied by spectacular commercial successes, at least not yet.  This raises a simple question: When will gene therapy fully realize its commercial potential? We explored that question with a distinguished panel on November 7, 2018 at the … Read More

Dealing with the Constant State of Launch in Oncology

Part Two in a Six-Part Series on Oncology Product Commercialization In Part One, we mentioned that the launch frequency for oncology products has increased significantly over the last several years.  While this trend is seen in other therapeutic areas across the industry, we believe the combination of factors driving this in oncology are somewhat unique … Read More

Key Commercial Challenges in Oncology

Part One in a Six-Part Series on Oncology Product Commercialization The oncology market continues to grow at a phenomenal pace, with worldwide revenues expected to increase from $104B in 2017 to $233B in 20241. Fueling this revenue growth is a rich pipeline, with more than 700 molecules in late-stage development – a 60% increase from … Read More

Demonstrating the Value of Rare Disease Treatments

Part V in a Series on Rare Diseases At various points in this series, we’ve mentioned that rare disease treatments are usually quite expensive.  In fact, the typical RD treatment costs between $300,000 and $750,000 (US) per year.1 Those high costs reflect two key realities:  1.) Developing new therapies is expensive and risky, and 2.) … Read More

Organizing to Enable the “High-Touch” Rare Disease Business Model

Part IV in a Series on Rare Diseases In Part I of this series, we introduced the fact that rare disease (RD) patients are quite special.  The same is true for the specialists who treat them.  In RD markets, these dynamics create the need for patient-centric treatment approaches and a “high-touch” business model with key … Read More

Rare Disease Centers of Excellence

Part III in a Series on Rare Diseases In parts I and II of this series, we provided an overview of the special commercial challenges associated with rare disease (RD) therapies, and we took a deeper dive into one of the most obvious:  Finding patients.   In this installment, we explore rare disease Centers of Excellence … Read More